Valuation
- Market cap
- 14,251,000
- Revenue TTM
- $40,000
- Net income TTM
- $-11,210,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -28,025.00%
- Debt to equity
- 0.00
Trading
- Volume
- 220,400
- Avg volume
- 2,261,819
- Day's range
- $6.10 – $6.98
- Shares out
- 2,239,000
- Stochastic %K
- 15%
- Beta
- 0.15
- Analysts
- Hold
- Price target
- $1.00
Company profile
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 60 9 08517 7330
- Website
- https://www.cyclacel.com
- Address
- Level 10, Tower 11 Avenue 5, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia
Latest news
No headlines yet.
